期刊
ADVANCED SCIENCE
卷 2, 期 11, 页码 -出版社
WILEY
DOI: 10.1002/advs.201500053
关键词
-
资金
- Portuguese Foundation for Science and Technology (FCT)
- European Community fund FEDER, through Program COMPETE [FCOMP01-0124-FEDER-021053 (PTDC/SAU-BMA/121028/2010), PEst-OE/EQB/LA0023/2013, RECI/BBB-EBI/0179/2012 (FCOMP-01-0124-FEDER-027462)]
- Programa Operacional Regional do Norte (ON. 2 - O Novo Norte), QREN, FEDER [NORTE-07-0124-FEDER-000027, NORTE-07-0124-FEDER-000028]
- FCT [SFRH/BD/51955/2012]
- [UID/BIO/04469/2013]
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-BMA/121028/2010, SFRH/BD/51955/2012] Funding Source: FCT
Triple negative breast cancer (TNBC) is a particular immunopathological subtype of breast cancer that lacks expression of estrogen and progesterone receptors (ER/PR) and amplification of the human epidermal growth factor receptor 2 (HER2) gene. Characterized by aggressive and metastatic phenotypes and high rates of relapse, TNBC is the only breast cancer subgroup still lacking effective therapeutic options, thus presenting the worst prognosis. The development of targeted therapies, as well as early diagnosis methods, is vital to ensure an adequate and timely therapeutic intervention in patients with TNBC. This review intends to discuss potentially emerging approaches for the diagnosis and treatment of TNBC patients, with a special focus on nano-based solutions that actively target these particular tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据